A consequence of our progressively ageing global population is the increasing prevalence
of worldwide age-related cognitive decline and dementia. In the absence of effective …

Alzheimer's disease (AD) is characterized by non-linear, genetic-driven pathophysiological
dynamics with high heterogeneity in biological alterations and disease spatial-temporal …

Abstract Introduction The Alzheimer's Disease Research Summits of 2012 and 2015
incorporated experts from academia, industry, and nonprofit organizations to develop new …

Progress toward the development of efficacious therapies for Alzheimer's disease (AD) is
halted by a lack of understanding early underlying pathological mechanisms. Systems …

Abstract Changes to lipid metabolism are tightly associated with the onset and pathology of
Alzheimer's disease (AD). Lipids are complex molecules comprising many isomeric and …

Choline is an essential nutrient for humans. It is a precursor of membrane phospholipids (eg,
phosphatidylcholine (PC)), the neurotransmitter acetylcholine, and via betaine, the methyl …

A major barrier to the effective conduct of clinical trials of new drug candidates against
Alzheimer's disease (AD) and to identifying patients for receiving future disease-modifying …

Alzheimer's disease (AD) is currently incurable, but there is general agreement that a
minimally invasive blood biomarker for screening in preclinical stages would be crucial for …

The recent failures of potential disease-modifying drugs for Alzheimer's disease (AD) may
reflect the fact that the enrolled participants in clinical trials are already too advanced to …

Introduction Identifying circulating metabolites that are associated with cognition and
dementia may improve our understanding of the pathogenesis of dementia and provide …